Shots:
- AstraZeneca has reported the global P-III (I CAN/ALXN1210-IgAN-320) trial assessing Ultomiris (IV) vs PBO in ~510 adults with IgAN who are at risk of disease progression
- Trial met its 1EP of reduced proteinuria based on 24-hr. UPCR at 34wks., with effect seen as early as 10wks., while the 1EP of change in eGFR will be measured at Wk. 106. AstraZeneca is planning accelerated approvals in key markets & will present the results at an upcoming conference
- Ultomiris is a long-acting C5 complement inhibitor that delivers immediate, complete, & sustained inhibition by blocking the C5 protein in the terminal complement cascade, preventing overactivation that can cause the immune system to attack healthy cells
Ref: AstraZeneca | Image: AstraZeneca | Press Release
Related News: AstraZeneca Reports Positive P-III (MIRANDA) Data for Tozorakimab in COPD
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
